SCHEMBL6760404

SCHEMBL6760404

COCOCc1c(I)ccnc1OC

nearest known ligand 0.30

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.30
TTK P33981 1/20 0.30
AURKB Q96GD4 1/20 0.30
INCENP Q9NQS7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1339029 0.81
SCHEMBL6435977 0.80
SCHEMBL6435979 0.80
SCHEMBL4402294 0.76 AURKA (0.33) AURKATTKAURKBINCENP
SCHEMBL4405916 0.76 AURKA (0.33) AURKATTKAURKBINCENP
SCHEMBL31437498 0.76 AURKA (0.33) AURKATTKAURKBINCENP
SCHEMBL23922826 0.75 CCNB2 (0.41) AURKATTKAURKBINCENP
SCHEMBL30677083 0.75 PTPN1 (0.30)
SCHEMBL6764287 0.73
SCHEMBL6764279 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6723853-B2 ANTICANCER AGENTS UNIVERSITY OF PITTSBURGH 2004-04-20 US disclosed
US-20030073840-A1 Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-04-17 US disclosed
WO-2003018559-A2 INTERMEDIATES AND PREPARATION THEREOF FOR THE ENANTIOSELECTIVE SYNTHESIS OF (20R) HOMOCAMPTOTHECINS UNIVERSITY OF PITTSBURGH (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073840-A1 Intermediates and methods of preparation of intermediates in the enantiomeric synthesis of (20R)homocamptothecins and the enantiomeric synthesis of (20R)homocamptothecins FOLR1, POR, FOLR2 AURKA 3270/4885TTK 3909/4885AURKB 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.